European ex-factory price development for global pharmaceutical companies in the context of the international price reference (ipr) framework. Impact of the german health care reform (amnog) on the european price development for innovative ...
May 1, 2013, 00:00 AM
10.1016/j.jval.2013.03.1232
https://www.valueinhealthjournal.com/article/S1098-3015(13)01303-X/fulltext
Section Title :
Respiratory-Related Disorders
Section Order :
812
First Page :
A242
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)01303-X&doi=10.1016/j.jval.2013.03.1232